Evidence map›Paper›PMID 36160883›Full record

ArticleExperimental and therapeutic medicine2022

1,2,3,4,6‑penta‑O‑galloyl‑β‑D‑glucose alleviates inflammation and oxidative stress in diabetic nephropathy rats through MAPK/NF‑κB and ERK/Nrf2/HO‑1 signaling pathways.

Dong Wang, Yan Li, Liheng Dai, Yanxia Wang, Congna Zhao, Wangang Wang, Yu Zhang, Yinrui Zhao, Tingting Yu

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Comprehensive Review on Fruit ofMolecules (Basel, Switzerland) · 2024
    Review
  6. Antioxidant 1,2,3,4,6-Penta-Molecules (Basel, Switzerland) · 2024
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dong WangDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Yan LiDepartment of Traditional Chinese Medicine, The Eighth People's Hospital of Qingdao, Shandong, Qingdao 266000, P.R. China.
Liheng DaiDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Yanxia WangDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Congna ZhaoDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Wangang WangDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Yu ZhangDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Yinrui ZhaoDepartment of Nephrology, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.
Tingting YuMedical Department, Beichen District Hospital of Traditional Chinese Medicine, Tianjin 300400, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy (DN) is one of the main causes of chronic renal failure, which is also the final cause of mortality in ~30% of diabetic patients. 1, 2, 3, 4, 6-penta-O-galloyl-β-D-glucose (PGG) from

Indexed as

1,2,3,4,6-penta-O-galloyl-β-D-glucosediabetic nephropathyinflammationoxidative stress

Identifiers

PMID36160883
PMCPMC9468796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.